William Mack & Associates’s Amneal Pharmaceuticals AMRX Stock Holding History

William Mack & Associates’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.01K	Buy	+100	New	+$1.8K	﹤0.01%	552

Other funds holding AMRX

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return

Neuberger Berman Group New York $148B AUM 31.56% 1-Year Est. Return

William Mack & Associates's AMRX Position: Q3 2026 in Review

William Mack & Associates opened a new position in Amneal Pharmaceuticals (AMRX) in Q3 2026: 100 shares worth $2.01K. The stake represents ﹤0.01% of the portfolio and ranks #552 among its holdings.

264 funds tracked by Wall St. Rank hold AMRX as of Q3 2026.

William Mack & Associates held 100 shares of Amneal Pharmaceuticals worth $2.01K as of Q3 2026.
Amneal Pharmaceuticals was a new William Mack & Associates position in Q3 2026.
Amneal Pharmaceuticals made up ﹤0.01% of William Mack & Associates's portfolio in Q3 2026, its #552 holding.
264 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q3 2026.

Based on William Mack & Associates's 13F filing for Q3 2026, filed 27 Oct 2026.